tetano
Editor, Senior Moderator
J Infect Public Health
. 2023 Mar 21;16(5):823-830.
doi: 10.1016/j.jiph.2023.03.019. Online ahead of print.
The association between inhaled corticosteroid and the risks of SARS-COV-2 infection: A systematic review and meta-analysis
Chao-Hsien Chen[SUP] 1 [/SUP], Ching-Yi Chen[SUP] 2 [/SUP], Chih-Cheng Lai[SUP] 3 [/SUP], Ya-Hui Wang[SUP] 4 [/SUP], Kuang-Hung Chen[SUP] 5 [/SUP], Cheng-Yi Wang[SUP] 6 [/SUP], Yu-Feng Wei[SUP] 7 [/SUP], Pin-Kuei Fu[SUP] 8 [/SUP]
Affiliations
Abstract
Background: The effect of inhaled corticosteroid (ICS) on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is unclear.
Methods: We performed a systematic review and meta-analysis of clinical studies that assessed the association between the use of ICS and the risk of SARS-COV-2 infection. PubMed, Web of Science, Scopus, Cochrane Library and Google Scholar were searched to January 1st, 2023. ROBINS-I was used to assess risk of bias of included studies. The outcome of interest was the risk of SARS-COV-2 infection in patients and odds ratio (OR) with 95% confidence interval (95% CI) were calculated using Comprehensive Meta-analysis software version 3.
Results: Twelve studies involving seven observational cohort studies, three case-control studies, and two cross-sectional studies were included in this meta-analysis. Overall, compared to non-ICS use, the pooled odds ratio (OR) of the risk of SARS-COV-2 infection was 0.997 (95% confidence interval [CI] 0.664-1.499; p = 0.987) for patients with ICS use. Subgroup analyses demonstrated no statistical significance in the increased risk of SARS-COV-2 infection in patients with ICS monotherapy or in combination with bronchodilators (pooled OR=1.408; 95% CI=0.693-2.858; p = 0.344 in ICS monotherapy, and pooled OR=1.225; 95% CI=0.533-2.815; p = 0.633 in ICS combination, respectively). In addition, no significant association was observed between ICS use and the risk of SARS-COV-2 infection for patients with COPD (pooled OR=0.715; 95% CI=0.415-1.230; p = 0.225) and asthma (pooled OR=1.081; 95% CI=0.970-1.206; p = 0.160).
Conclusions: The use of ICS, either monotherapy or in combination with bronchodilators, does not have impact on the risk of SARS-COV-2 infection.
Keywords: COPD; COVID-19; Inhaled corticosteroid; Risk; SARS-CoV-2.
. 2023 Mar 21;16(5):823-830.
doi: 10.1016/j.jiph.2023.03.019. Online ahead of print.
The association between inhaled corticosteroid and the risks of SARS-COV-2 infection: A systematic review and meta-analysis
Chao-Hsien Chen[SUP] 1 [/SUP], Ching-Yi Chen[SUP] 2 [/SUP], Chih-Cheng Lai[SUP] 3 [/SUP], Ya-Hui Wang[SUP] 4 [/SUP], Kuang-Hung Chen[SUP] 5 [/SUP], Cheng-Yi Wang[SUP] 6 [/SUP], Yu-Feng Wei[SUP] 7 [/SUP], Pin-Kuei Fu[SUP] 8 [/SUP]
Affiliations
- PMID: 37003028
- DOI: 10.1016/j.jiph.2023.03.019
Abstract
Background: The effect of inhaled corticosteroid (ICS) on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is unclear.
Methods: We performed a systematic review and meta-analysis of clinical studies that assessed the association between the use of ICS and the risk of SARS-COV-2 infection. PubMed, Web of Science, Scopus, Cochrane Library and Google Scholar were searched to January 1st, 2023. ROBINS-I was used to assess risk of bias of included studies. The outcome of interest was the risk of SARS-COV-2 infection in patients and odds ratio (OR) with 95% confidence interval (95% CI) were calculated using Comprehensive Meta-analysis software version 3.
Results: Twelve studies involving seven observational cohort studies, three case-control studies, and two cross-sectional studies were included in this meta-analysis. Overall, compared to non-ICS use, the pooled odds ratio (OR) of the risk of SARS-COV-2 infection was 0.997 (95% confidence interval [CI] 0.664-1.499; p = 0.987) for patients with ICS use. Subgroup analyses demonstrated no statistical significance in the increased risk of SARS-COV-2 infection in patients with ICS monotherapy or in combination with bronchodilators (pooled OR=1.408; 95% CI=0.693-2.858; p = 0.344 in ICS monotherapy, and pooled OR=1.225; 95% CI=0.533-2.815; p = 0.633 in ICS combination, respectively). In addition, no significant association was observed between ICS use and the risk of SARS-COV-2 infection for patients with COPD (pooled OR=0.715; 95% CI=0.415-1.230; p = 0.225) and asthma (pooled OR=1.081; 95% CI=0.970-1.206; p = 0.160).
Conclusions: The use of ICS, either monotherapy or in combination with bronchodilators, does not have impact on the risk of SARS-COV-2 infection.
Keywords: COPD; COVID-19; Inhaled corticosteroid; Risk; SARS-CoV-2.